Researchers have discovered a new way to optimize results in treating patients with prostate cancer tumors while minimizing negative side effects. The study is featured in the November issue of the Journal of Nuclear Medicine.
According to the Centers for Disease Control, “Aside from non-melanoma skin cancer, prostate cancer is the most common cancer among men in the United States. It is also one of the leading causes of cancer death among men of all races.”
Prostate-specific membrane antigen (PSMA) is an important target for nuclear medicine imaging of prostate cancer and subsequent PSMA-targeted radionuclide therapy. This combination of diagnostic imaging and therapy targeted on a feature of the identified tumors is called theranostics. The aim of this study was to evaluate the change in the whole-body distribution of the imaging agent fluorine-18 (18F)-PSMA-1007 when solutions with different peptide concentrations are used.
For the study, a mouse xenograft model was used, with the mice divided into three groups according to the peptide concentration injected (high, medium and low concentration/molar activity levels). A decrease in the peptide concentration (or molar activity) level resulted in decreased uptake in the tumor and, to a greater degree, in the salivary glands.
Source: Read Full Article